Skip to Content
  • Previous Rank
    34
  • Revenues ($M)
    $136,809.00
  • Revenue Percent Change
    5.3%
  • Profits ($M)
    $256
  • Profits Percent Change
    -80.1%
  • Assets ($M)
    $39,951.00
  • Employees
    50,200

The $136.8 billion revenue drug wholesaler and medical supplier managed 5.3% sales growth in 2018 despite an increasingly challenging environment, largely due to greater sales of high-price drugs used in oncology, among other medical specialties. The bulk of Cardinal’s revenue comes from the medications it distributes to pharmacies, and is impacted by fluctuations in drug prices. The declining price of generics has weighed on the company’s bottom line in recent years, and heightened scrutiny of drug pricing has created uncertainty for Cardinal and its two bigger rivals, McKesson and AmerisourceBergen. The industry is also under continued pressure—and faces a growing number of lawsuits—over its alleged role in the nation’s opioid epidemic.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

CEO
Michael C. Kaufmann
Sector
Health Care
Industry
Wholesalers: Health Care
HQ Location
Dublin, Ohio
Websitehttps://www.cardinalhealth.com
Years on Global 500 List22
Employees50,200
Figures are for fiscal year ended June 30, 2018.

Cardinal Health Rank History

placeholder

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$136,809.005.3%
Profits ($M)$256-80.1%
Assets ($M)$39,951.00-
Total Stockholder Equity ($M)$6,059.00-

Profit Ratios

Profit as % of Revenues0.2%
Profits as % of Assets0.6%
Profits as % of Stockholder Equity4.2%